Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
$115B
P/E ratio
26×
Div yield
0%
Revenue
$12B
Net income
$4B
Rev. growth
+8%
Cash & securities
$13B
2026 rev. guidance
~$13B
In plain English
Vertex owns cystic fibrosis: its Trikafta/Kaftrio and next-generation Alyftrek pills treat the underlying disease for the vast majority of CF patients worldwide and throw off ~$12B a year. It is now spending that cash to diversify — Casgevy, the first approved CRISPR gene-editing therapy (co-developed with CRISPR Therapeutics), the non-opioid pain drug Journavx, an islet-cell therapy aiming to cure type-1 diabetes, and a kidney-disease pipeline bought via Alpine Immune.
In simple terms
What Vertex Pharmaceuticals really sells
Vertex owns cystic fibrosis: its Trikafta/Kaftrio and next-generation Alyftrek pills treat the underlying disease for the vast majority of CF patients worldwide and throw off ~$12B a year. It is now spending that cash to diversify — Casgevy, the first approved CRISPR gene-editing therapy (co-developed with CRISPR Therapeutics), the non-opioid pain drug Journavx, an islet-cell therapy aiming to cure type-1 diabetes, and a kidney-disease pipeline bought via Alpine Immune.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.